Atacicept
- Generic Name
- Atacicept
- Drug Type
- Biotech
- CAS Number
- 845264-92-8
- Unique Ingredient Identifier
- K3D9A0ICQ3
- Background
Atacicept is a recombinant fusion protein combined with the extracellular ligand binding portion of TACI.
- Indication
Investigated for use/treatment in autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, multiple myeloma, lymphoma (non-hodgkin's), and leukemia (lymphoid).
Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2016-12-30
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 27
- Registration Number
- NCT00664521
- Locations
- 🇬🇧
Research Site, Norwich, United Kingdom
A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2016-05-24
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 255
- Registration Number
- NCT00642902
- Locations
- 🇬🇧
Research Site, Stoke on Trent, United Kingdom
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 461
- Registration Number
- NCT00624338
- Locations
- 🇺🇸
Justus J. Fiechtner, MD, MPH, Lansing, Michigan, United States
🇺🇸Inland Rheumatology Clinical Trials Inc, Upland, California, United States
🇬🇧Research Site, Manchester, United Kingdom
Atacicept in Subjects With Optic Neuritis
- Conditions
- Optic Neuritis
- Interventions
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 34
- Registration Number
- NCT00624468
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 311
- Registration Number
- NCT00595413
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center, Darmstadt, Germany
🇺🇸Please Contact US Medical Information, Rockland, Massachusetts, United States
The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis
- Conditions
- Lupus Nephritis
- Interventions
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 6
- Registration Number
- NCT00573157
- Locations
- 🇺🇸
1711 St. Julian Place, Columbia, South Carolina, United States
🇺🇸The Feinstein Institute for Medical Research, Manhasset, New York, United States
🇲🇾Hospital Sultanah Bahiyah, Kedah, Malaysia
A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 256
- Registration Number
- NCT00430495
- Locations
- 🇨🇦
Merck/Serono, Canada, Canada
🇺🇸EMD Serono, Rockland, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.